Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR

Asthma disease burden1

Airway icon
Airway icon

According to the CTS guidelines, asthma has a national prevalence of 10.8% and affects 3.8 million Canadians over the age of 1 year.

  • The majority of Canadians with asthma continue to have suboptimal control and severe asthma exacerbations.
  • Asthma-related deaths are still occurring at a rate of 6.2 per 100,000.

Data for SYMBICORT TURBUHALER on the rate of severe or moderate asthma exacerbations are presented elsewhere in this site. SYMBICORT TURBUHALER’s effect on morbidity and mortality have not been evaluated as predefined endpoints in prospectively designed, well-controlled, randomized trials.

For more information, review the latest CTS guidelines for asthma.

View asthma guidelines

COPD disease burden2,3

Lung icon
Lung icon

COPD affects 2.0 million Canadians aged 35 and older, and COPD-related deaths were occurring at a rate of 22.2 per 1,000 in 2011-2012.

According to the CTS guidelines, COPD can result in a high burden of disease reflected in health status, morbidity, and mortality.

  • Acute exacerbations* lead to a faster lung function decline, worsened health status, and increased hospitalizations.
  • Severe exacerbations are also associated with increased all-cause mortality.

Data for SYMBICORT TURBUHALER on the rate of severe or moderate COPD exacerbations, and health status (SGRQ) are presented elsewhere in this site. SYMBICORT TURBUHALER’s effect on morbidity and mortality have not been evaluated as predefined endpoints in prospectively designed, well-controlled, randomized trials.

For more information, review the latest CTS guidelines for COPD.

View COPD guidelines

COPD: chronic obstructive pulmonary disease; CTS: Canadian Thoracic Society; SGRQ: St. George’s Respiratory Questionnaire.

* The CTS COPD guidelines define a COPD exacerbation as an acute worsening of respiratory symptoms that may require the use of antibiotics, systemic corticosteroids, and/or healthcare services. A moderate COPD exacerbation requires a prescription for an antibiotic and/or oral corticosteroids, whereas a severe COPD exacerbation requires hospitalization or an emergency department visit.

References:

  1. Yang CL et al. 2021 Canadian Thoracic Society Guideline – A focused update on the management of very mild to mild asthma. Can J Respir Crit. 2021;5(4):205–245.
  2. Health Canada. Report from the Canadian chronic disease surveillance system: asthma and chronic obstructive pulmonary disease (COPD) in Canada. 2018.
  3. Bourbeau J, et al. 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPD. Can J Respir Crit Care Sleep Med. 2023;7(4):173–191.
Back to top